Top Pharmaceutical Companies in Boston, MA (130)
Who We Are Chewy is where pet parents find everything they need for life with pets, from food to fun to pharmacy. We make pet care easier, more informed, and more joyful through fast, reliable delivery and award-winning 24/7 Customer Care, including access to pet health support when it’s needed. Founded in 2011, Chewy combines the convenience of online shopping with...
Chewy's Top Stability & Growth Strengths
Customer Loyalty & Retention: Autoship accounts for the vast majority of sales (over four-fifths) and is growing faster than total revenue, indicating a sticky, recurring base and higher retention. Evidence includes Autoship representing ~83% of FY2025 net sales and ~84.6% in Q2 FY2026 with high single‑digit to double‑digit growth.
Profitability: Operating metrics show expanding earnings power, with adjusted EBITDA up materially and margins improving alongside strong free cash flow. Observations include FY2025 adjusted EBITDA growth of ~26% with margin expansion and additional year‑over‑year gains reported in 1H FY2026.
Strong Market Position & Advantage: Chewy is characterized as the largest U.S. pet e‑tailer and a leading online pet‑supplies platform by GMV and digital presence, underpinning durable scale advantages. Multiple summaries highlight leadership in online pet retail, substantial Autoship penetration, and strong digital search share versus specialty peers.
Formation Bio is a tech-driven pharma company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes all aspects of drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data capture. Formation Bio acquires clinical-stage drugs from pharma and biotech and develops them faster and more efficiently, unlocking greater...
Formation Bio's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Capital raising has accelerated, including a $372M Series D in 2024 with total funding reported in the hundreds of millions to expand the pipeline and AI platform. Valuation has stepped up from roughly $1.04B (2021) to about $1.48B post‑money (2024), signaling strengthened private‑market positioning.
Strategic Partnerships: Partnerships are expanding, highlighted by a collaboration with Sanofi and OpenAI to build AI software for drug development and increased business‑development capacity via Entrepreneurs in Residence. Engagements with large pharma partners, including Sanofi, underscore growing external validation and deal flow.
Product Line Growth: The pipeline is broadening through multiple in‑licenses—such as an anti‑CD226 program, a CNS‑penetrant TYK2 inhibitor, and a miR‑124 activator—and progression to first‑in‑human dosing of BLKR201 in 2026. Stated plans to reach 10–15 assets over 3–5 years align with recent portfolio expansion and clinical advancement.
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Schrödinger, Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: Recent results indicate total revenue increased year over year in 2025 and continued to rise in the latest reported quarter. Guidance and quarterly updates point to ongoing top-line expansion even as mix shifts occur.
Resilient & Sustainable Growth: Underlying annual contract value expanded and accelerated in 2026, with management indicating continued growth despite the transition to hosted licensing. This suggests the core subscription base is strengthening even when reported revenue timing varies.
Diversified Revenue Streams: Growth is visible in both the software business and the milestone-driven drug discovery segment. The latter stepped up meaningfully in recent periods, complementing steady software momentum.
Valo is a technology company built to transform the drug discovery and development process using human-centric data and AI-powered computation. Valo is fully integrating human-centric data across the entire drug development lifecycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing the cost, time, and failure rate. The company’s Opal Computational Platform™...
The Broad Institute of MIT and Harvard is an independent, non-profit biomedical and genomic research organization. Its mission is to understand the roots of disease and close the gap between new biological insights and impact for patients. By convening cross-disciplinary teams of scientists, the institute aims to discover the root causes of all common and rare diseases to develop safe...
The Bill & Melinda Gates Medical Research Institute is a non-profit organization dedicated to the development and effective use of novel biomedical interventions addressing substantial global health concerns, for which investment incentives are limited. The institute works through collaborating partners and organizations, coordinating and driving the full spectrum of biopharmaceutical development activities, including pre-clinical development, full clinical development (from phase...
Dompé is an Italian bio-pharmaceutical company that focuses on innovation, where a long tradition in the field of personal wellness goes hand in hand with a commitment to research and development to meet hitherto unsatisfied therapeutic needs. Established in 1940 in Milan, Dompé continues to have its headquarters in this city. In Italy, it also has offices in L’Aquila, with an...
Azurity Pharmaceuticals is a privately held, specialty pharmaceutical company that focuses on innovative products that meet the needs of patients with underserved conditions. As an industry leader in providing unique, accessible, and high-quality medications, Azurity leverages its integrated capabilities and vast partner network to continually expand its broad commercial product portfolio and robust late-stage pipeline. The company’s patient-centric products span...
OM1 is an insights-driven technology and data company specializing in Personalized Medicine, Evidence Generation, and RWE Research powered by next-Gen A.I. platforms, regulatory-grade deep longitudinal data, and globally recognized thought leadership. Our unprecedented innovation takes RWE from Bench-to-Practice, delivering unparalleled personalized impact on the outcomes of patients and the advancement of research. We do things differently. We are pushing the boundaries...
Headquartered in Dedham, Mass., AliMed is a specialty medical supplies manufacturer and distributor with on-site customization capabilities and a vast portfolio of healthcare products designed to improve patient outcomes and experiences. Celebrating 50 years of serving patient needs spanning “hospital to home,” AliMed has built its long history and strong reputation on responsiveness, exceptional customer service, and high-quality offerings. Visit AliMed.com...
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader medicines for serious diseases, including oncology, autoimmune, inflammatory, cardiovascular, and cardiometabolic conditions. Its QuEEN platform combines proprietary molecular glue libraries with proteomics, structural biology, computational chemistry, and AI/machine learning to discover and develop treatments aimed at disease-driving proteins and pathways long considered undruggable across multiple therapeutic...
Invivyd is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. Invivyd’s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with the potential to resist viral escape. The...
Advancing knowledge to improve lives.™ We are a global strategic partner with decades of experience across the entire life sciences product lifecycle. We excel in providing our clients with unique insights and efficiencies to support them in their journey to improve health outcomes and ultimately the quality of people’s lives. By connecting our full suite of products and services from scientific...
Eli Lilly and Company engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment. For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of...
Eli Lilly and Company's Top Stability & Growth Strengths
Strong Market Position & Advantage: By market value and category leadership in incretins, Lilly sits at or near the top of global pharma. Mounjaro/Zepbound are redefining obesity/diabetes, with Mounjaro becoming the world’s best‑selling prescription drug in early 2026.
Strong Revenue Growth: Results show outsized, volume-led acceleration, with Q1 2026 revenue reaching $19.8B. Management also raised 2026 sales guidance to about $82–$85B after very strong 2025 growth.
Innovation-Driven Growth: Recent approvals and pipeline progress beyond metabolic disease add new growth pillars. The FDA approval of Kisunla (donanemab) in 2024 and advancement of oral GLP‑1 programs broaden the portfolio.
Life Molecular Imaging (LMI) is an international pharma company dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. The organization strives to be a leader in the molecular imaging field. Our mission is to pioneer innovative PET products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic...
Procter & Gamble Company is an American multi-national consumer goods corporation. P&G was founded over 180 years ago as a soap and candle company. Today, we’re the world’s largest consumer goods company and home to iconic, trusted brands, including Always®, Charmin®, Braun®, Fairy®, Febreze®, Gillette®, Head & Shoulders®, Oral B®, Pantene®, Pampers®, Tide®, and Vicks®. The design, development, growth and...
Procter & Gamble's Top Stability & Growth Strengths
Strong Market Position & Advantage: P&G is consistently characterized as the clear industry leader with dominant positions across core categories, anchored by flagship brands like Tide, Pampers, Gillette, Crest, and Oral‑B. Multiple sources in the provided materials frame it as leading peers across home care, baby/feminine, grooming, and oral care.
Innovation-Driven Growth: The company is repeatedly recognized for leadership in product innovation and is advancing new formats and data‑driven operations to sustain momentum. References cite top‑ranked innovation in household products for multiple consecutive years and highlight launches such as new detergent formats.
Resilient & Sustainable Growth: Recent updates indicate a return to positive unit volumes with modest organic sales and EPS increases, alongside reaffirmed low single‑digit growth guidance. Dividend increases and ongoing cash returns are emphasized as continuing, underscoring a steady, durable profile.
Ardelyx is a publicly traded biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs. Ardelyx's first approved product, IBSRELA® (tenapanor) is available in the United States. Ardelyx is developing XPHOZAH® (tenapanor), a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed...
Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Our lead molecule, azetukalner, is a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). We are also advancing an early-stage portfolio...
Resilience (National Resilience, Inc.) is a first-of-its-kind manufacturing and technology company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the medicines of today and tomorrow can be made quickly, safely, and at scale
Resilience (resilience.com).'s Top Stability & Growth Strengths
Investor Backing & Capital Strength: The company is described as well-funded, with multiple sizable financing events including up to $825M in long-term financing to accelerate its CDMO strategy and prior large equity rounds. Public-sector funding and government-backed initiatives are also cited as signals of confidence in its role in domestic manufacturing and supply-chain resilience.
Strategic Partnerships: The business has landed recognizable relationships such as an AstraZeneca fill/finish deal and earlier work with Takeda, which help validate its capabilities and quality expectations. Additional collaborations with research institutions are positioned as strengthening its advanced-therapy offering.
Future-Ready Strategy: The operating model is oriented toward complex modalities (biologics, vaccines, nucleic acids, cell and gene therapy) with drug substance and fill/finish capabilities, positioning it toward segments expected to remain strategically important. The post-2025 pivot toward a smaller set of “go-forward” hubs is framed as a refocus on higher-demand areas like sterile drug product and selected biologics/cell-therapy capabilities.
